43598-2 |
Indicans |
PrThr |
Urine |
24H |
Ord |
|
|
ACTIVE |
Indicans [Presence] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
43598-2 |
|
|
|
|
Both |
|
|
|
0 |
Indicans 24h Ur Ql |
|
|
|
N |
|
1 day; 24 hours; 24HR; Chemistry; Indoxyl sulfate; Ordinal; PR; QL; Qual; Qualitative; Screen; UA; UR; Urn |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
43599-0 |
HIV 1 Ab |
ACnc |
Ser |
Pt |
Qn |
IF |
|
ACTIVE |
HIV 1 Ab [Units/volume] in Serum by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
43599-0 |
|
IF |
|
|
Both |
|
|
|
0 |
HIV1 Ab Ser IF-aCnc |
|
|
|
N |
|
ABS; Aby; ACIF; AIDS; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Arbitrary concentration; Autoantibodies; Autoantibody; FA; Fluorescent antibody; Fluoresent; HIV type 1; HIV type I; HIV1; Human immunodeficiency virus; i; ID; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Infectious Disease; InfectiousDisease; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; Time Resolved Fluorescence; TRF |
2.69 |
2.17 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
436-6 |
Rolitetracycline |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Rolitetracycline [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
436-6 |
|
MIC |
|
|
Observation |
|
|
|
0 |
Rolitetracycline Islt MIC |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; PMT; Point in time; Pyrrolidinomethyltetracycline; Random; Reverin; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Transcycline |
2.19 |
1 |
|
|
|
|
|
|
|
|
|
|
|
0 |
4360-4 |
Normetanephrine |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Normetanephrine [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4360-4 |
|
|
|
|
Observation |
|
|
|
0 |
Normetanephrine Dose |
|
|
|
Y |
|
Dose med or substance; DRUG DOSES; Normeta; Normetaneph; Normetanephrn; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
43600-6 |
Ganglioside GD1b Ab.IgM |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Ganglioside GD1b IgM Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
43600-6 |
|
|
|
|
Both |
|
|
|
0 |
GD1b Gangl IgM Ser Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Disialolganglioside; Disialylganglioside; GD1b; GD1b Gangl; Immune globulin M; Immunoglobulin M; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serology; Serum; SR |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
43601-4 |
Ganglioside GD1b Ab.IgG |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Ganglioside GD1b IgG Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
43601-4 |
|
|
|
|
Both |
|
|
|
0 |
GD1b Gangl IgG Ser Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Disialolganglioside; Disialylganglioside; GD1b; GD1b Gangl; Immune globulin G; Immunoglobulin G; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serology; Serum; SR |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
43602-2 |
Echinococcus granulosus Ab |
ACnc |
Ser |
Pt |
Qn |
IA |
|
ACTIVE |
Echinococcus granulosus Ab [Units/volume] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
43602-2 |
|
IA |
|
|
Both |
|
|
|
0 |
E granulosus Ab Ser IA-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; E granulosus; Echinococcosis; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; ID; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; SUDS |
2.69 |
2.17 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
43603-0 |
Androstenedione^1st specimen post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Androstenedione [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
43603-0 |
|
|
|
|
Observation |
|
|
|
0 |
Androst sp1 p chal SerPl-mCnc |
|
|
|
N |
|
Acute specimen; After; CHEMISTRY.CHALLENGE TESTING; First; gamma-4-Androstenedione; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; Pre immunization; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; sp1; sp1 p chal; Spec; SR |
2.73 |
2.17 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
43604-8 |
Aldosterone^1st specimen post XXX challenge |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Aldosterone [Mass/volume] in Serum or Plasma --1st specimen post XXX challenge |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
43604-8 |
|
|
|
|
Observation |
|
|
|
0 |
Aldost sp1 p chal SerPl-mCnc |
|
|
|
N |
|
Acute specimen; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; First; Level; Mass concentration; p chal; Pl; Plasma; Plsm; Point in time; Pre immunization; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; sp1; sp1 p chal; Spec; SR |
2.73 |
2.17 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
43605-5 |
Albumin |
MCnc |
Urine |
4H |
Qn |
Detection limit <= 20 mg/L |
|
ACTIVE |
Microalbumin [Mass/volume] in 4 hour Urine |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHEM |
|
43605-5 |
|
Detection limit <= 20 mg/L |
|
|
Both |
|
|
|
0 |
Microalbumin 4h Ur-mCnc |
|
|
|
N |
|
240 minutes; 4 hours; 4.0Hr; 4HR; Alb; Chemistry; DL=20 mg/L; Kidney; Left; Level; Levo; MA; Malb; Mass concentration; Micro albumin; Microalbumin; Nephrology; Protein.albumin; QNT; Quan; Quant; Quantitative; Renal; UA; UR; Urn |
2.34 |
2.17 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
43606-3 |
Albumin |
MRat |
Urine |
4H |
Qn |
Detection limit <= 20 mg/L |
|
ACTIVE |
Microalbumin [Mass/time] in 4 hour Urine |
|
MIN |
DefinitionDescription |
|
|
ug/min |
|
|
|
|
|
|
CHEM |
|
43606-3 |
|
Detection limit <= 20 mg/L |
|
|
Both |
|
|
|
0 |
Microalbumin 4h Ur-mRate |
|
|
|
N |
|
240 minutes; 4 hours; 4.0Hr; 4HR; Alb; Chemistry; DL=20 mg/L; Kidney; Left; Levo; MA; Malb; Mass rate; Micro albumin; Microalbumin; mRate; Nephrology; Protein.albumin; QNT; Quan; Quant; Quantitative; Renal; UA; UR; Urn |
2.3 |
2.17 |
|
|
|
|
|
|
|
ug/min |
|
|
|
0 |
43607-1 |
Albumin |
MRat |
Urine |
12H |
Qn |
Detection limit <= 20 mg/L |
|
ACTIVE |
Microalbumin [Mass/time] in 12 hour Urine |
|
MIN |
DefinitionDescription |
|
|
ug/min |
|
|
|
|
|
|
CHEM |
|
43607-1 |
|
Detection limit <= 20 mg/L |
|
|
Both |
|
|
|
0 |
Microalbumin 12h Ur-mRate |
|
|
|
N |
|
12 hours; 12HR; Alb; Chemistry; DL=20 mg/L; Kidney; Left; Levo; MA; Malb; Mass rate; Micro albumin; Microalbumin; mRate; Nephrology; Protein.albumin; QNT; Quan; Quant; Quantitative; Renal; UA; UR; Urn |
2.3 |
2.17 |
|
|
|
|
|
|
|
ug/min |
|
|
|
0 |
43608-9 |
Adrenal cortex Ab |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Adrenal cortex Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
43608-9 |
|
|
|
|
Both |
|
|
|
0 |
Adrenal cortex Ab Ser Ql |
|
|
|
N |
|
ABS; Aby; ACA; Adrnl; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serology; Serum; SR |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
43609-7 |
Adipate |
PrThr |
Urine |
24H |
Ord |
|
|
ACTIVE |
Adipate [Presence] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
43609-7 |
|
|
|
|
Both |
|
|
|
0 |
Adipate 24h Ur Ql |
|
|
|
N |
|
1 day; 24 hours; 24HR; Adipic acid; Chemistry; Hexanedioate; Hexanedioic acid; Ordinal; PR; QL; Qual; Qualitative; Screen; UA; UR; Urn |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
4361-2 |
Nortriptyline |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Nortriptyline [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4361-2 |
|
|
|
|
Observation |
|
|
|
0 |
Nortrip Dose |
|
|
|
Y |
|
Amitriptyline metabolite; Aventyl; Dose med or substance; DRUG DOSES; Nortrip; Nortriptylene; Nortriptyln; Pamelor; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
43610-5 |
Adenovirus Ag |
PrThr |
Nph |
Pt |
Ord |
IF |
|
ACTIVE |
Adenovirus Ag [Presence] in Nasopharynx by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
43610-5 |
|
IF |
|
|
Both |
|
|
|
0 |
HAdV Ag Nph Ql IF |
|
|
|
N |
|
ACIF; Adeno virus; Anticomplement Immunofluorescence; Antigen; Antigens; DFA; FA; Fluorescent antibody; Fluoresent; HAdV; ID; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Infectious Disease; InfectiousDisease; Microbiology; Nasopharynx; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Time Resolved Fluorescence; TRF |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
43611-3 |
Adenovirus Ag |
PrThr |
Bronchial |
Pt |
Ord |
IF |
|
ACTIVE |
Adenovirus Ag [Presence] in Bronchial specimen by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
43611-3 |
|
IF |
|
|
Both |
|
|
|
0 |
HAdV Ag Bronch Ql IF |
|
|
|
N |
|
ACIF; Adeno virus; Anticomplement Immunofluorescence; Antigen; Antigens; Bro; DFA; FA; Fluorescent antibody; Fluoresent; HAdV; ID; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Infectious Disease; InfectiousDisease; Lung; Microbiology; Ordinal; Point in time; PR; Pulmonary; Pulmonology; Ql; Qual; Qualitative; Random; Respiratory; Screen; Time Resolved Fluorescence; TRF |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
43612-1 |
Adenovirus Ag |
PrThr |
Nose |
Pt |
Ord |
IF |
|
ACTIVE |
Adenovirus Ag [Presence] in Nose by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
43612-1 |
|
IF |
|
|
Both |
|
|
|
0 |
HAdV Ag Nose Ql IF |
|
|
|
N |
|
ACIF; Adeno virus; Anticomplement Immunofluorescence; Antigen; Antigens; DFA; FA; Fluorescent antibody; Fluoresent; HAdV; ID; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Infectious Disease; InfectiousDisease; Microbiology; Nasal; Nos; Nose (nasal passage); Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Smell; Time Resolved Fluorescence; TRF |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
43613-9 |
Adenovirus Ag |
PrThr |
Trac |
Pt |
Ord |
IF |
|
ACTIVE |
Adenovirus Ag [Presence] in Trachea by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
43613-9 |
|
IF |
|
|
Both |
|
|
|
0 |
HAdV Ag Trachea Ql IF |
|
|
|
N |
|
ACIF; Adeno virus; Anticomplement Immunofluorescence; Antigen; Antigens; DFA; FA; Fluorescent antibody; Fluoresent; HAdV; ID; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Time Resolved Fluorescence; Trachea; TRF |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
43614-7 |
Adenovirus Ag |
PrThr |
Nose |
Pt |
Ord |
|
|
ACTIVE |
Adenovirus Ag [Presence] in Nose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
43614-7 |
|
|
|
|
Both |
|
|
|
0 |
HAdV Ag Nose Ql |
|
|
|
N |
|
Adeno virus; Antigen; Antigens; HAdV; ID; Infectious Disease; InfectiousDisease; Microbiology; Nasal; Nos; Nose (nasal passage); Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Smell |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
43615-4 |
Adenovirus Ag |
PrThr |
Genital |
Pt |
Ord |
|
|
ACTIVE |
Adenovirus Ag [Presence] in Genital specimen |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
43615-4 |
|
|
|
|
Both |
|
|
|
0 |
HAdV Ag Genital Ql |
|
|
|
N |
|
Adeno virus; Antigen; Antigens; Gen; Genital tract; HAdV; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Urogenit; Urogenital |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
43616-2 |
Adenovirus Ab |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Adenovirus Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
43616-2 |
|
|
|
|
Both |
|
|
|
0 |
HAdV Ab Ser Ql |
|
|
|
N |
|
ABS; Aby; Adeno virus; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; HAdV; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
43617-0 |
Adenovirus Ab |
PrThr |
CSF |
Pt |
Ord |
|
|
ACTIVE |
Adenovirus Ab [Presence] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
43617-0 |
|
|
|
|
Both |
|
|
|
0 |
HAdV Ab CSF Ql |
|
|
|
N |
|
ABS; Aby; Adeno virus; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; HAdV; ID; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
43618-8 |
Adenovirus Ab |
PrThr |
Ser |
Pt |
Ord |
Comp fix |
|
ACTIVE |
Adenovirus Ab [Presence] in Serum by Complement fixation |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
43618-8 |
|
Comp fix |
|
|
Both |
|
|
|
0 |
HAdV Ab Ser Ql CF |
|
|
|
N |
|
ABS; Aby; Adeno virus; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; CF; Comp fixation; Compfix; Complement fixation; HAdV; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.73 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
43619-6 |
Actinomyces sp Ab |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Actinomyces sp Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
43619-6 |
|
|
|
|
Both |
|
|
|
0 |
Actinomyces Ab Ser Ql |
|
|
|
N |
|
ABS; Aby; Actino; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; species; spp; SR |
2.56 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |